Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899583 | 0.86 | APEX1 (0.69) | ALDH1A1HSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL13593519 | 0.84 | LMNA (0.63) | ALDH1A1HSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL10686326 | 0.84 | ALDH1A1 (0.60) | ALDH1A1HSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL11109767 | 0.83 | HSD17B10 (0.46) | ALDH1A1HSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL11354000 | 0.81 | ALDH1A1 (0.65) | ALDH1A1HSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL7403091 | 0.80 | LMNA (0.59) | ALDH1A1HSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL11464349 | 0.80 | LMNA (0.62) | ALDH1A1HSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL10920133 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL16209547 | 0.79 | ALDH1A1 (0.54) | ALDH1A1HSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL14965898 | 0.79 | ALDH1A1 (0.54) | ALDH1A1HSD17B10LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003245-A | Preparation method of 2-hydroxy-3-oxopentane diacid | 苏州永健生物医药有限公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-1490356-B1 | (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1490356-B1 | (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-7060844-B2 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
| EP-1490356-A1 | (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040019098-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003084951-A1 | (3Z) -3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | ALDH1A1 1528/4885HSD17B10 3034/4885LMNA 3833/4885 |
| US-20040019098-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | ALDH1A1 1606/4885HSD17B10 3073/4885LMNA 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.